Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device

Version 1 : Received: 6 April 2022 / Approved: 8 April 2022 / Online: 8 April 2022 (03:27:23 CEST)
Version 2 : Received: 5 June 2022 / Approved: 6 June 2022 / Online: 6 June 2022 (05:53:21 CEST)

How to cite: Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints 2022, 2022040069 (doi: 10.20944/preprints202204.0069.v1). Ishikawa, T.; Kodama, E.; Kobayashi, T.; Azumi, M.; Nozawa, Y.; Iwanaga, A.; Sano, T.; Honma, T. Efficacy of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma with Glass Membrane Emulsification Device. Preprints 2022, 2022040069 (doi: 10.20944/preprints202204.0069.v1).

Abstract

Background: Transarterial chemoembolization (TACE) is the standard treatment for BCLC-B hepatocellular carcinoma (HCC). The glass membrane emulsification device (GMD), a novel device, produces a high percentage of water/oil emulsions with homogeneous and stable droplets. There are few reports on the efficacy of GMD-conventional-TACE (GMD-c-TACE). We aimed to evaluate the efficacy of GMD-c-TACE. Methods: Seventy-one patients with HCC of tumor diameter <5 cm who underwent c-TACE with and without GMD were included in this study to investigate local recurrence and hepatic functional reserve. Results: Local recurrence rates without GMD-TACE was 3.0% at 6 months, 16.7% at 12 months, 35.0% at 18 months, and it then plateaued. Hence, the local recurrence rate in the GMD-c-TACE group was 7.7% at 14 months and 23.1% at 20 months, respectively. GMD-c-TACE had a significantly lower local recurrence. Multivariate analysis showed that GMD-c-TACE could suppress local recurrence and maintain the hepatic reserve. Conclusions: GMD-c-TACE allows dense accumulation of lipiodol in the tumor and attainment of good local control. Additionally, the inhibition of the release of anticancer drugs may maintain the hepatic reserve. GMD-c-TACE is useful in preventing local recurrence and is expected to become the standard treatment form of c-TACE in the future.

Keywords

hepatocellular carcinoma; conventional transarterial chemoembolization; emulsion; lipiodol; glass membrane emulsification device

Subject

MEDICINE & PHARMACOLOGY, Gastroenterology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.